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A metal ion regulated artificial metalloenzyme 
 
Regulation of enzyme activity is essential in living cells. The rapidly 
increasing number of designer enzymes with new-to-nature activities makes 
it necessary to develop strategies for controlling their catalytic activity. This 
chapter describes the development of an LmrR-based metal ion regulated 
artificial metalloenzyme created by simultaneously introducing a regulatory 
and a catalytic site into the protein. The catalytic activity of the artificial 
metalloenzyme is turned on in presence of Fe2+ ions, while addition of Zn2+ 









Part of this chapter has been published: 





4.1.1 Control of activity of artificial metalloenzymes 
Control over enzymatic activity is vital for regulating the complex network of 
biosynthetic pathways in living cells. Nature employs several strategies to achieve 
tight regulation of enzymatic activity; these include control of enzyme concentration, 
substrate/product inhibition, (ir)reversible covalent modification or proteolysis.1 
Another important strategy used by nature to control enzyme activity is allosteric 
regulation, that is binding of an effector molecule or a metal ion at a site in the protein 
other than the active pocket.2–4 As a result of this interaction, the catalytic activity of 
an enzyme and, therefore, its activity in a biosynthetic pathway, can be regulated by 
the presence or absence of chemical signals in the environment.  
In recent years several designer enzymes with new-to-nature activities have been 
developed.5–7 With the advance of synthetic biology and the perspective of 
incorporating these designer enzymes in the complex chemical network of the cell, 
the need for developing regulatory mechanisms for their activity increases. 
Additionally, these artificial enzymes could be of interest for other applications, for 
example as (bio)sensors.  
Artificial metalloenzymes are hybrid catalysts that incorporate non-natural metal 
cofactors into biological scaffolds, thereby giving access to enzyme-like catalysts 
with non-natural catalytic activities.8,9 A wide variety of artificial metalloenzymes 
that display such activities within a biomolecular host has been presented in 
literature.10–12 A future challenge in the research of artificial metalloenzymes is their 
incorporation into the cellular environment. On one hand such developments would 
allow for faster optimization and evolution of these hybrid catalysts to achieve 
superior activities and, on the other hand, it would constitute a major advance for 
synthetic biology. The presence of the protein host in an artificial metalloenzyme 
has been shown to increase the bio-compatibility of the transition metal complex, 
therefore enabling its use in combination with natural enzymes for cascade 
reactions.13–15 Moreover, the first example of an artificial metalloenzyme harboring 
an abiotic cofactor able to perform catalysis in vivo was recently reported.16  
However, examples of such hybrid enzymes that can be activated by mechanisms 
akin to allosteric control remain scarce. Indeed, the only two examples for this type 
of activation come from the Ward group, who has recently demonstrated that the 
activity of artificial asymmetric transfer hydrogenases could be upregulated by 
proteolysis when a natural protease is used as an external stimulus or cross-regulated 
by coupling the artificial metalloenzyme with a natural enzyme that produces an 
inhibitor for its activity (Chapter 1, Figure 16).17,18  
A metal ion regulated artificial metalloenzyme 
87 
 4 
4.1.2 LmrR-based artificial metalloenzymes 
Over the past years our group has introduced a novel class of artificial 
metalloenzymes based on the transcriptional regulator LmrR (Lactococcal multidrug 
resistance Regulator). LmrR is a small homodimeric protein with a size of 14 kDa 
per subunit and it belongs to the PadR-like family of transcriptional regulators in 
Lactococcus Lactis.19,20 LmrR shows the typical structural feature of PadR proteins 
with the N-terminal β-winged helix-turn-helix motif involved in DNA binding and 
the additional C-terminal helix involved in dimerization. These C-terminal helices 
form a large, symmetrical and flat central pore at the subunit interface 
(approximately 22 Å in width and 6 Å in height) that can accommodate a large 
spectrum of small aromatic molecules for multi drug resistance.21 This hydrophobic 
pore presents two entrances. The front entrance (helices α4-α4’) is predominantly 
comprised by negatively charged amino acids and is probably involved in attracting 
the positively charged drugs. Conversely, the largely positively charged back 
entrance (helices α1-α1’ and α3-α3’) is involved in DNA binding.21 Ligand binding 
inside the pocket of LmrR is mainly achieved by hydrophobic interactions and 
aromatic stacking between the tryptophan residues in positions 96 and 96’ (Figure 
1).  
 
Figure 1: Surface representation of the front entrance of LmrR (PDB 3F8F).21 Zoom in of the 
hydrophobic pocket at the dimer interface. Tryptophans in positions 96 and 96’ are shown in blue. 
This cavity at the dimer interface is attractive for creating a new active site for 
artificial metalloenzymes as it combines a chiral second coordination sphere with a 
hydrophobic microenvironment that is suitable for binding small molecule 
substrates. To date a few examples of LmrR-based artificial metalloenzymes applied 
for enantioselective catalysis have been described.22–25 Another attractive feature of 
LmrR as biomolecular scaffold for artificial metalloenzymes is its amenability 
toward three different anchoring strategies for incorporating non-natural cofactors. 
Covalent22,23 and supramolecular anchoring,25 as well as unnatural amino acid 
incorporation,24 have been used to introduce transition metal complexes or 
non-natural metal binding moieties. The resulting hybrid catalysts have been applied 
in a variety of Lewis acid catalyzed enantioselective reactions, including Diels-Alder 
cycloaddition,22 water addition to α,β-unsaturated ketones23 and Friedel–Crafts 





Figure 2: Schematic representation of LmrR-based artificial metalloenzymes applied for 
enantioselective reactions based on three different anchoring strategies for the incorporation of 
non-natural cofactors: unnatural amino acid incorporation,24 covalent anchoring22,23 and 
supramolecular anchoring.25 
4.2 Aim  
In this project the possibility of regulating the activity of an LmrR-based 
metalloenzyme with metal ions was investigated. For the creation of a metal 
regulated artificial metalloenzyme two different metal binding sites needed to be 
introduced within the biomolecular scaffold of LmrR: a catalytic site, where the 
desired transformation takes place, and a regulatory site to bind the regulatory metal 
ions that will activate or inactivate the metalloenzyme. 
4.3 Design 
In order to introduce two different metal complexes within the LmrR scaffold we 
took advantage of the design versatility of LmrR and combined two different 
anchoring strategies. The incorporation of a catalytic site via the supramolecular 
approach is based on the binding of Cu2+ complexes of planar aromatic ligands (such 
as phenanthroline) between the two tryptophans located inside the hydrophobic 
pocket of LmrR (positions 96 and 96′, Figure 1). This approach has been previously 
applied to catalyze the enantioselective Friedel–Crafts alkylation of α,β-unsaturated 
imidazoles to indoles using Cu2+ phenanthroline complexes, such as 
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[Cu(phen)(NO3)2], obtaining good conversions and excellent enantioselectivities of 
>90%.25 The introduction of a regulatory site via covalent anchoring of a metal 
binding moiety to LmrR is based on the site-selective modification of the protein 
using a unique cysteine as bioconjugation handle for the alkylation reaction.22,23 
Since LmrR is a homodimeric protein, the introduction of a ligand in one specific 
position via covalent anchoring will lead to functionalization of both monomers, 
resulting in a dimeric protein containing two metal binding moieties. 
The design of the envisioned metal ion regulated artificial metalloenzyme is 
depicted in Figure 3. In absence of an effector metal ion, the metal binding moieties 
covalently anchored to LmrR will bind the catalytically active complex 
[Cu(phen)(NO3)2]. As a result, the two free coordination sites on the Cu2+ required 
for substrate binding are sequestered, rendering the artificial metalloenzyme 
inactive. Conversely, addition of transition metal ions that bind stronger than Cu2+, 
would trap the metal binding moieties into stable chelate complexes, allowing the 
active Cu2+ complex to perform the catalysis (Figure 3).  
 
 
Figure 3: Schematic representation of the metal ion regulated artificial metalloenzyme 
Previous work with LmrR based metalloenzymes showed that enantioselective 
reactions take place inside the hydrophobic pocket in close proximity to the front 
entrance. Therefore, it was envisioned that the formation of chelate metal complexes 
in this area might also impact catalysis.22,23 2,2′-Bipyridine was selected as metal 
binding moiety for the regulatory site due to its ability to strongly bind late-first row 
transition metal ions with high affinity and in different stoichiometries.26–30 The 
bipyridine ligands were introduced on solvent exposed positions on the α4 helices, 
which delimit the front entrance of the hydrophobic pocket. Introduction of 
bipyridine ligands on these helices would allow the formation of chelate complexes 
involving one bipyridine moiety of each monomer. Positions 93 and 104, located in 
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the central part of the front entrance, and position 86, which is located toward the 
edge of the pocket, were chosen for the introduction of the ligands (Figure 4). 
 
Figure 4: Surface and helix representation of the LmrR front entrance. Residues H86, F93, E104 
are shown in blue, green and red, respectively. 
4.4 Results and discussion 
4.4.1 Synthesis and characterization of LmrR_bipyridine conjugates 
Plasmids encoding C-terminally Strep-tagged cysteine mutants of LmrR (F93C, 
E104C, H86C) were prepared by standard site-directed mutagenesis technique 
(Quik-Change) from a vector available from previous work (Table 4).22 LmrR 
mutants were subsequently expressed in E. coli BL21(DE3) C43 and purified first 
by affinity chromatography (Strep-tactin Sepharose column) and then by cation 
exchange chromatography (Heparin column) to remove residual bound DNA. Target 
proteins were obtained in good yields (10–20 mg/L) and in excellent purity as judged 
by Tricine-SDS-PAGE, UPLC-MS (Table 5) and analytical size exclusion 
chromatography. 
Bipyridine units were introduced by selective alkylation of cysteines with a 
bromoacetamide derivative of 2,2′-bipyridine (Figure 5).22,23 UPLC-MS (Table 6) 
and Tricine-SDS-PAGE were used to confirm identity and purity of the 
LmrR_bipyridine conjugates and analytical size exclusion chromatography 
demonstrated that the dimeric structure of LmrR was not significantly altered by 
introduction of the metal binding moieties (Figure 12). 
 
Figure 5: Reaction scheme of the synthesis of LmrR_bipyridine conjugates. Ligand used for 
alkylation reaction on LmrR cysteine mutants: N-([2,2’-bipyridin]-5-ylmethyl)-2-
bromoacetamide.31,32 
With the LmrR bipyridine conjugates in hand, the binding of these conjugates to 
Zn2+ and Fe2+ was studied by UV-visible titrations. These two ions are examples of 
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divalent, late-first row transition metal ions with different coordination properties. 
Upon addition of either metal salt, the appearance of a shoulder around 310 nm was 
observed, indicative of a change in the π–π* transition of the bipyridine upon metal 
coordination (Figure 7). This red shift has previously been reported for bipyridine 
ligands in solution and for proteins containing a bipyridine moiety.29,32,33 
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Figure 6: UV-visible titrations of LmrR F93C_bpy (a), LmrR E104C_bpy (b) and LmrR H86C_bpy 
(c) with FeSO4·7H2O (left) and Zn(NO3)2·6H2O (right). Titrations were performed in 50 mM 
NaH2PO4 pH 7.0, 500 mM NaCl with 22.5 µM LmrR_bipyridine conjugate (dimer) with 
subsequent additions from 1 mM solutions of metal salts in milliQ water. Insets show the fitting of 
the titration data obtained with non-linear regression. 
In the titration with Fe2+ also the appearance of two additional absorption bands 
between 490 and 530 nm was observed. These bands are characteristic of 
Fe2+-bipyridine complexes (Figure 6).28,30,34,35 The resulting titration curves could be 
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fitted to a 1:1 binding model, corresponding to the formation of complexes 
containing one metal ion per LmrR dimer (Table 1). The stoichiometry of the 
metal:protein complexes was further confirmed by Job’s plot, in which the maximum 
complex formation was obtained with equimolar concentrations of metal ions and 
LmrR dimer (Figure 7).  
ICP-AES experiments performed after incubation of the 
LmrR_E104C_bipyridine conjugate with Fe2+ and Zn2+, followed by dialysis to 
remove unbound metal ions, also suggested the presence of one equivalent of metal 
ion per LmrR dimer. 









































X Zn2+  
Figure 7: Job’s plot graphs of LmrR_bipyridine conjugates with FeSO4·7H2O (left) and 
Zn(NO3)2·6H2O (right). Plots of ΔA at 530 nm for Fe2+ and 311 nm for Zn2+ against the molar 
fraction (x) of the Fe2+ and Zn2+, respectively. 100 µM stock solutions of LmrR conjugates in 50 
mM NaH2PO4 pH 7.0, 500 mM NaCl and 200 µM of FeSO4·7H2O or Zn(NO3)2·6H2O in milliQ 
water. Total concentration in the cuvette was kept constant at 60 µM. 
Taken together these observations suggest the formation of a chelate metal 
complex between one metal ion and two bipyridines in the LmrR scaffold. 
Exogenous water molecules or ligands supplied by amino acid side chains might 
complete the coordination sphere around the metal. The formation of a chelate 
complex between the two bipyridines and the metal ions was expected for the 
conjugates containing bipyridine units located in the central part of the front entrance 
(LmrR F93C_bpy and LmrR E104C_bpy), given the proximity of the two amino 
acids in the protein dimer (10–15 Å from the reported crystal structure).21 However, 
for the conjugate in which the bipyridine ligands are located towards the edge of the 
hydrophobic pocket (LmrR H86C_bpy) the formation of a chelate metal complex 
appeared unlikely due to the distance between the two residues in position 86 (28–
30 Å).21 Tentatively, chelation of the metal ions could be achieved due to the known 
flexibility of the LmrR scaffold. The cost for the formation of these less favored 
complexes is reflected in a lower binding affinity for both regulatory metals (Table 
1) and an apparent lower stability of the metal-bound proteins, which were prone to 
precipitation. However, the possibility of formation of chelate complexes with 
bipyiridine units from separate LmrR dimers should also be considered, as suggested 
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by the presence of higher order aggregates in the size exclusion chromatography of 
some Fe2+ conjugates (LmrR E104C_bpy and LmrR H86C_bpy) (Figure 12). 
 
4.4.2 Catalysis 
The catalytic activity of the LmrR_bipyridine conjugates and their metal complexes 
was evaluated in the enantioselective, vinylogous Friedel–Crafts alkylation of 
1-(1-methyl-1H-imidazol-2-yl)but-2-en-1-one (1) with 2-methyl-1H-indole 
(2).24,25,36–38 The metal complexes of LmrR bipyridine conjugates with Fe2+ and Zn2+ 
(LmrR_bpy_M2+) were prepared fresh prior to catalysis by incubation of 1 
equivalent of the corresponding metal salt with 1 equivalent of the LmrR_bpy 
conjugate (dimer) in 20 mM MOPS pH 7.0,  500 mM NaCl. The mixtures were 
centrifuged to remove possible precipitate and the supernatants containing the 
LmrR_bpy_M2+ complexes were used for the supramolecular assembly of the 
artificial metalloenzymes. The artificial metalloenzymes were prepared in situ by 
self-assembly from [Cu(phen)(NO3)2] (22 μM) with a slight excess (1.3 equivalents) 
of LmrR_bpy_M2+ complex (30 μM) in 20 mM MOPS pH 7.0, 500 mM NaCl. The 
mixtures were incubated at 4 °C for 30 minutes and the catalytic reactions were 
initiated by addition of substrates 1 and 2 at a final concentration of 1 mM each. 
Reactions were incubated at 4 °C for 72 hours, after which the products were 
extracted and analyzed by chiral HPLC.  
As previously reported, the reaction of 1 with 2 catalyzed by the assembly of 
[Cu(phen)(NO3)2] with wt-LmrR was protein accelerated and gave rise to excellent 
enantioselectivity (92%, Table 2, entries 1 and 2).25  
As expected, using the LmrR_bipyridine conjugates in absence of any regulatory 
metal ion resulted in no significant catalytic activity of the metalloenzymes with 
LmrR F93C_bpy and LmrR E104C_bpy and low activity for LmrR H86C_bpy 
(Table 2, entries 3–5). These results are consistent with the absence of free 
coordination sites on the Cu2+ ion in the [Cu(phen)(NO3)2] complex, being 
sequestered by the conjugated bipyridine ligands and thus preventing substrate 
binding (Figure 3). For LmrR H86C_bpy, this sequestration is apparently less 
Table 1 Dissociation constants for LmrR_bipyridine conjugates with Fe2+ and Zn2+ 
determined by UV-visible titrations 
Entry Protein KD (µM) 
1 LmrR F93C_bpy+Fe2+ 1.2±0.5 
2 LmrR F93C_bpy+Zn2+ 1.5±0.5 
3 LmrR E104C_bpy+Fe2+ 1.0±0.3 
4 LmrR E104C_bpy+Zn2+ 0.304±0.005 
5 LmrR H86C_bpy+Fe2+ 4.8±0.2 
6 LmrR H86C_bpy+Zn2+ 7±1 
 
The reported apparent dissociation constants (KD) are the average of two independent experiments 
performed with two independent batches of LmrR_bipyridine conjugates and the errors correspond to the 
standard deviation.  
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efficient for reasons not understood at the moment, as indicated by the low activity 
of the conjugates.  
For the conjugate LmrR F93C_bpy formation of metal complexes with either 
Fe2+ or Zn2+ prior to catalysis resulted in no significant product formation (Table 2, 
entries 6 and 7). The observed lack of catalytic activity might be due to the bulkiness 
of the chelate metal complexes that are located right in the middle of the front 
entrance, preventing the substrates to reach the active Cu2+ center located inside. 
This hypothesis is supported by the observation that no binding of the dye Hoechst 
33342, which is known to access the hydrophobic pocket of LmrR through the front 
entrance, to LmrR F93C_bpy was observed using fluorescence spectroscopy (Figure 
8).21 















eq H33342:LmrR  
Figure 8: Fluorescence titrations of LmrR_bipyridine conjugates with Hoechst 33342. Titrations 
were performed with 0.2 µM solutions of protein dimer in 20 mM MOPS pH 7.0, 500 mM NaCl 
with subsequent additions from a 8 µM solution of Hoechst 33342 in milliQ water.  
For LmrR E104C_bpy and LmrR H86C_bpy on the other hand, we were pleased 
to observe catalytic activity upon incubation with the regulatory metal ions (Fe2+ or 
Zn2+), prior to addition of the active [Cu(phen)(NO3)2] complex (Table 2, entries 8–
10), albeit lower than the activity observed for wt-LmrR. These results suggest that 
the activity of these artificial metalloenzymes can indeed be regulated by the 
presence of metal ions.  
It was observed consistently that activation with Fe2+ yielded more active 
artificial metalloenzymes when compared to the addition of Zn2+: higher turnover 
numbers (TON) were achieved for the artificial metalloenzymes containing Fe2+ 
complexes compared to the respective Zn2+ complexes (Table 1, entries 8–11). As 
this difference in activity is particularly pronounced for the conjugate LmrR 
E104C_bpy (7 times higher TON of the Fe2+ complex compared to the respective 
Zn2+ complex) this variant was selected for further investigation.  
According to the Irving–Williams series, six-coordinate octahedral Cu2+ 
complexes are thermodynamically more stable than other high spin divalent first row 
transition metal complexes. Thus, in our design, the Cu2+ from the active 
[Cu(phen)(NO3)2] complex could replace Zn2+ from the high spin bipyridine 
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complex, forming a mixed complex with phenanthroline and the covalently bound 
bipyridine as ligands. Since this additional interaction would prevent substrate 
binding, the resulting artificial metalloenzyme becomes inactive towards the desired 
reaction. Conversely, Fe2+ is known to predominantly form low spin complexes with 
bipyridine ligands, which are kinetically more stable and, as a result, less prone to 
ligand substitution. Therefore, exchange of Fe2+ by Cu2+ will not occur and the 
artificial metalloenzyme will remain active.39,40 
 
To test this hypothesis, reactions were performed using an excess of Fe2+ or Zn2+ 
ions. The LmrR_E104C_bpy conjugates were incubated with 1, 3 and 6 equivalents 
of metal ions and in case of Zn2+ also 10 equivalents (with respect to LmrR dimer) 
before the artificial metalloenzyme was assembled by addition of [Cu(phen)(NO3)2]. 
As expected, when additional Fe2+ equivalents were added, no significant change in 
catalytic activity was observed (Figure 9). In contrast, when going from 1 to 10 
equivalents of Zn2+, an increase in activity was detected (from 4 to 12 TON, Figure 
9). With increasing amounts of Zn2+ also a decrease in enantioselectivity was 
evident, which presumably reflects structural changes of the chiral active site as a 




Table 2 Results of vinylogous Friedel−Crafts alkylation reactions catalyzed by LmrR_bpy 
conjugates and their respective Fe2+ and Zn2+ complexes. 
 
 
Entry Catalyst Yield (%)a TONb ee (%)c 
1 Cu(phen)(NO3)2 (only) 39±4 16±2 <5 
2 wt-LmrR 58±3 24±1 92±1 (-) 
3 LmrR F93C_bpy ≤1 - n.d. 
4 LmrR E104C_bpy ≤1 - n.d. 
5 LmrR H86C _bpy 7±1 3±1 81±4 (-) 
6 LmrR F93C _bpy+Fe2+ 2±0 1±0 n.d. 
7 LmrR F93C _bpy+Zn2+ 2±1 1±1 n.d. 
8 LmrR E104C_bpy+Fe2+ 34±4 14±2 75±6 (-) 
9 LmrR E104C_bpy+Zn2+ 4±0 2±0 n.d. 
10 LmrR H86C _bpy+Fe2+ 26±6 11±2 88±3 (-) 
11 LmrR H86C_bpy+Zn2+ 14±2 6±1 80±10 (-) 
 
Typical conditions: 2.2 mol% [Cu(phen)(NO3)2] (22 µM) loading with 1.3 eq LmrR_bpy conjugates (30 µM), 
1 mM of substrate 1 and 2 in 20 mM MOPS pH 7.0, 500 mM NaCl, for 72 h at 4 °C. All the results listed 
correspond to the average of two independent experiments, each carried out in duplicate. aYields were 
determined by HPLC and using 2-phenylquinoline as internal standard. bTurnover numbers (TON) were 
determined by dividing the concentration of product by the catalyst concentration. cSign of rotation was 
assigned based on the elution order in chiral HPLC by comparison to previous reports.36,38 For yields below 









Figure 9: Comparison of turnover numbers (TON, black) and enantioselectivity (purple) in the 
vinylogous Friedel−Crafts alkylation reactions catalyzed by LmrR_E104C_bpy and respective 
Fe2+ and Zn2+ complexes in presence of increasing concentration of Fe2+ (left) and Zn2+ (right). 
Same reaction conditions as in Table 2.  
The possibility of a metal exchange between the regulatory metal ion (Fe2+ or 
Zn2+) and the catalytic metal ion (Cu2+) was further investigated by ICP-AES 
measurements. LmrR_E104C_bpy_M2+ complexes were formed, thoroughly 
dialyzed to remove non-bound metal ions,  incubated with Cu2+ ions, dialyzed again, 
and the regulatory metal ion (Fe2+ or Zn2+) bound to the protein was quantified. 
Quantification of the regulatory metal bound to the protein after incubation with 
[Cu(phen)(NO3)2] did not show a change in the total amount of Fe2+ or Zn2+ (Figure 
11 and Table 7) because metal exchange might result in the formation a mixed Cu2+ 
phenanthroline-bipyridine complex, while the regulatory metal will still be bound to 
the second bipyridine in the LmrR scaffold (Figure 10).  
a) 
 
     b) 
 
Figure 10: Schematic representation of metal ion exchange between regulatory metal ion (M2+) 
and the catalytic metal ion (Cu2+) with (a) [Cu(phen)(NO3)2] and (b) Cu(NO3)2. 
In order to drive the equilibrium towards a complete metal replacement, leading 
to a Cu2+ bis-bipyridine complex and the release of the regulatory metal ion, 
incubation of the LmrR_bpy_M2+ complexes with Cu(NO3)2 was performed (Figure 
10). A significant decrease in the amount of Zn2+ bound to the protein was observed 
after incubation with Cu(NO3)2 (Figure 11 and Table 7), confirming the hypothesis 
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of a partial replacement of Zn2+ with Cu2+, with subsequent inactivation of the 
catalyst (Figure 10). The observation that the metal displacement reaction does not 
seem to take place for the Fe2+ complex supports the formation of a stable low spin 










































Figure 11: Results of ICP-AES measurements on LmrR_E104C_bpy complexes with Fe2+ (left) 
and Zn2+ (right). Percentage of the regulatory metal ion bound to LmrR is normalized to the 
amount of Fe2+ or Zn2+ quantified upon incubation of LmrR bipyridine conjugates with 1 eq of 
metal ion and subsequent dialysis (black bar).   
Lastly, we tested the reversibility of the designed metal regulated artificial 
metalloenzyme by inverting the order of addition of the regulatory and catalytic 
metal ions. Toward this end, LmrR_E104C_bpy was first incubated with the active 
catalyst ([Cu(phen)(NO3)2]) at 4 °C for 30 minutes followed by addition of 1 
equivalent of regulatory metal ion salt (Fe2+ or Zn2+). After incubation of the 
resulting mixture for 30 minutes substrates 1 and 2 were added at a final 
concentration of 1 mM each. In parallel, LmrR_E104C_bpy was also incubated first 
with Fe2+ or Zn2+ and then with [Cu(phen)(NO3)2]. Reactions were incubated at 4 °C 
for 72 h, after which the products were isolated and analyzed by chiral HPLC.  
 
We were delighted to observe that catalytic activity (as well as enantioselectivity) 
could be restored to a large extent upon addition of Fe2+ salt to the inactive 
metalloenzyme (Table 3, entry 1 and 2). In contrast, addition of Zn2+ salt resulted in 
very low catalytic activity in either case (Table 3, entry 3 and 4). This result suggests 
Table 3 Effect of the order of incubation on the results of vinylogous Friedel−Crafts alkylation reactions 
catalyzed by the [Cu(phen)(NO3)2]  / LmrR E104C_bpy conjugate. 
Entry 1st incubation 2nd incubation Yield (%)a TONb ee (%)c 
 LmrR E104C_bpy     
1 Fe2+ [Cu(phen)(NO3)2] 57±14 23±5 72±14 (-) 
2 Cu(phen)(NO3)2] Fe
2+ 33±5 14±2 78±2 (-) 
3 Zn2+ [Cu(phen)(NO3)2] 13±2 6±1 50±1 (-) 
4 [Cu(phen)(NO3)2] Zn
2+ 11±3 5±1 50±13 (-) 
 
Same reaction conditions as in Table 2. aYields were determined by HPLC and using 2-phenylquinoline 
as internal standard. bTurnover numbers (TON) were determined by dividing the concentration of product 
by the catalyst concentration. cSign of rotation was assigned based on the elution order in chiral HPLC by 
comparison to previous reports.36,38  For yields below 5% ee’s  were not determined.  
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that selective regulation of activity of the designed artificial metalloenzyme by Fe2+ 
ions is reversible.  
4.5 Conclusions 
In conclusion, in this chapter the successful design, synthesis and characterization of 
a metal ion regulated artificial metalloenzyme are presented. By combining a 
regulatory site to bind an effector metal ion and an active site to recruit a catalytically 
active metal complex to the LmrR scaffold, the activity of an artificial 
metalloenzyme for the enantioselective vinylogous Friedel–Crafts alkylation of the 
α-β unsaturated imidazole 1 with 2-methyl indole 2 could be regulated by incubation 
with Fe2+ ions. Reminiscent of allosteric regulation in natural enzymes, we achieved 
selective activation by Fe2+ but not by Zn2+, taking advantage of the different 
coordination properties of these transition metals. This study represents the first 
example of a metal ion regulated artificial metalloenzyme and presents a significant 
advance toward controlling the activity of designer enzymes in hybrid bio-synthetic 
pathways. Application of this strategy in vivo is not yet a possibility, due to the 
necessary post-translational modification required for the installation of the 
regulatory site (bipyridine moieties covalently anchored to the LmrR scaffold). Once 
an efficient protocol for the presented reaction in vivo will be available, designing 
the regulatory site with unnatural metal binding amino acids (such as 
(2,2-bipyridin-5yl)alanine) might be considered in order to avoid the 
post-translational modification step. Complications related with possible 
competition of naturally occurring metal ions with the regulatory metal ions (Fe2+ or 
Zn2+) should also be considered. 
4.6 Experimental section 
4.6.1 General remarks 
Chemicals were purchased from Sigma Aldrich or Acros and used without further purification. 
1H-NMR and 13C-NMR spectra were recorded on a Varian 400 MHz in CDCl3 or DMSO-d6. 
Chemical shifts (δ) are denoted in ppm using residual solvent peaks as internal standard. 
Enantiomeric excess determinations were performed by HPLC analysis using UV-detection 
(Shimadzu SCL-10Avp). Conditions: Chiralpak AD-H, n-heptane:iPrOH 88:12, 45 min, 0.5 
ml/min. For reversibility experiments conditions: Chiralpak AD, n-heptane:iPrOH 90:10, 30 min, 
1.0 ml/min. UPLC-MS on protein samples was performed on a Acquity TQ Detector (ESI 
TQD-MS) coupled to Waters Acquity Ultra Performance LC using a Acquity BEH C8 (1.7 µm 2.1 
x 150 mm). Water (solvent A) and acetonitrile (solvent B) containing 0.1% formic acid by volume, 
were used as the mobile phase at a flow rate of 0.3 mL/min. Gradient: 90% A for 2 min, linear 
gradient to 50% A in 2 min, linear gradient to 20% A in 5 min, followed by 2 min at 5% A. 
Re-equilibration of the column with 2 min at 90% A. UPLC-MS chromatograms were analyzed 
with MassLynx V4.1 and deconvolution of spectra was obtained with the algorithm MagTran.41  
ICP-AES analysis was performed with a Perkin Elmer Optima 7000DV instrument. 
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Tricine-SDS-PAGE were performed in minigel BioRad apparatus and Coumassie staining was 
obtained with InstantBlue (Expedeon). Markers used for Tricine-SDS-PAGE: PageRuler™ 
Unstained Broad Range Protein Ladder and PageRuler™ Unstained Low Range Protein Ladder 
(Thermo Scientific). Ultra-centrifugation was performed with Vivaspin-Turbo-15 or Vivaspin-500 
(Sartorius). Fluorescence and UV-visible spectra were recorded on Jasco FP-6200 
spectrofluorometer and Jasco V-660 spectrophotometer, respectively. E. coli strains NEB5α and 
BL21 (DE3) C43 (Stratagene) were used for cloning and protein production, respectively. PCR 
reactions were carried out using an Eppendorf Mastercycler Personal apparatus. DNA sequencing 
was carried out by GATC-Biotech. Primers were synthesized by Eurofins. Pfu Turbo polymerase 
was purchased from Agilent and DpnI was purchased from New England Biolabs. Plasmid 
Purification Kit was purchased from Qiagen. Äkta Purifier 900 (GE Healthcare) was used for Fast 
Protein Liquid Chromatography (FPLC). FPLC columns Hi-Trap heparin HP and Superdex75 
10/300 GL were purchased from GE Healthcare. Strep-tag purification was performed on 
Strep-Tactin superflow resin (IBA) and dialysis membrane was purchased by SpectrumLabs. 
Concentration of the proteins was measured with Nanodrop 2000 (Thermo Scientific). Extinction 
coefficients of protein (ε280) were calculated by Protparam tool on the Expasy server (contribution 
of bipyridine moiety was accounted for by addition the measured extinction coefficient obtained 
for 2,2’-bipyridine (ε=14800 M-1cm-1) to the extinction coefficient of the protein.  
4.6.2 Synthesis 
 
N-([2,2’-bipyridin]-5-ylmethyl)-2-bromoacetamide was synthesized 
according to a literature procedures as reported in Chapter 3.22,31,32,42 
(E)-1-(1-Methyl-1H-imidazole-2-yl)-but-2-en-1-one (1) was 
synthesized according to a literature procedure36 starting from 861 mg of crotonic 
acid (10 mmol) with a 24% yield (360 mg, 2.4 mmol). 1H NMR (400 MHz, CDCl3) 
δ (ppm): 7.37 (m, 1H), 7.12 (m, 1H), 7.09-7.04 (m, 1H), 7.01 (s, 1H), 4.00 (s, 3H), 
1.95 (d, J=6.9 Hz, 3H). 
 
[Cu(phen)(NO3)2] was synthesized according to a literature procedure.43 
Elemental analysis: C % 39.10, H % 2.15, N % 15.21 (calculated: C % 39.19, 
H % 2.19, N % 15.23).  
A racemic mixture of the Friedel–Crafts product 
1-(1-methyl-1H-imidazol-2-yl)-3-(2-methyl-1H-indol-3-yl)butan-1-one 
(3) as reference material was synthesized adapting a literature 
procedure.25,44 (E)-1-(1-methyl-1H-imidazole-2-yl)-but-2-en-1-one (50 mg, 
0.33 mmol) and the 2-methyl indole (86 mg, 0.66 mmol), predissolved in 1 
mL acetonitrile each, were added to 500 mL of water containing 1.2 g sodium dodecyl sulfate (4.2 
mmol, 8 mM final concentration) and 15 mol% Cu(NO3)2.3H2O (0.05, 12 mg). The reaction was 
stirred at room temperature for 16 hours. 5 g of NaCl were added and the aqueous phase was 
extracted 3 times with 100 mL diethyl ether. The combined organic phases were washed with 100 
mL brine and dried over Na2SO4. The product was purified by column chromatography 
(ethylacetate: heptane 1:1) and obtained as a yellow solid with a 52% yield (54 mg, 0.19 mmol). 
1H NMR (400 MHz, CDCl3) (δ, ppm): 1.47 (d, J=9.2 Hz, 3H), 2.39 (s, 3H), 3.62 (d, J=10.4 Hz, 
2H), 3.76-3.78 (m, 1H), 3.7 (s, 3H), 6.91 (s, 1H), 7.00-7.06 (m, 1H), 7.10 (s, 1H), 7.19-7.20 (m, 
1H), 7.64-7.67 (m, 1H), 7.72 (s, 1H). 
4.6.3 Site-directed mutagenesis 
pET17b plasmids encoding for cysteine mutants of LmrR including a C-terminal Strep-tag for 
purification purposed prepared by site-directed mutagenesis (Quik Change) starting from a plasmid 
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available from previous work.22 The primers used for the mutagenesis are listed in Table 4. 
Standard Pfu Turbo DNA polymerase protocol was used with an initial denaturation at 95 °C for 
1 min. The following cycle was repeated 16 times: denaturation at 95 °C for 30 s, annealing at 52 
°C for 1 min, elongation at 72 °C for 4 minutes. Final elongation was performed at 72 °C for 10 
min. The resulting PCR products were digested with restriction endonuclease DpnI for 1 h at 37 
°C and 5 µL of the mixture were directly transformed into the E. coli NEB5α. Cells were spread 
onto an agar plate containing 100 μg/mL of ampicillin. Single colonies were selected after 
overnight growth and used to inoculate 5 mL of LB medium containing the same antibiotic. 
Plasmids were isolated by plasmid purification kit and sequences were confirmed by Sanger 
sequencing (T7 forward primer).  
 
4.6.4 Expression and purification 
pET17b plasmids encoding for LmrR mutants were transformed into E. coli BL21 (DE3) C43 
which were spread onto an agar plate containing 100 μg/mL of ampicillin. Single colonies were 
selected after overnight growth and used to inoculate 5 mL of LB medium containing the same 
antibiotic. This starter culture was grown at 37 °C overnight and used to inoculate 500 mL of fresh 
LB medium with the same antibiotic. The culture was grown at 37 °C until OD600 = 0.8 
(approximately 3h) and then isopropyl β-D-1-thiogalactopyranoside (IPTG) at final concentration 
of 1 mM was added to induce the expression of the target proteins. Protein expression was 
performed at 30 °C overnight. Cells were harvested by centrifugation (6000 rpm, JA‐10, 20 min, 
4 °C) and the pellets were resuspended in 50 mM NaH2PO4 pH 8.0, 150 mM NaCl, 2.5 mM DTT 
(20 mL, no DTT present for wt-LmrR) containing a protease inhibitor cocktail (Complete, Roche). 
Cells were sonicated (70% (200W) for 10 min (10 sec on, 15 sec off) after which a PMSF solution 
(final concentration 0.1 mM) and DNaseI (0.1 mg/mL, containing 10 mM MgCl2) were added. The 
cell-free extracts obtained after centrifugation (15000 rpm, JA-17, 45 min, 4 °C) were then loaded 
into columns containing 3 mL of pre‐equilibrated slurry of Strep-Tactin column material (50% 
Strep-Tactin in storage buffer) for 1 h at 4 °C (mixed at 200 rpm on a rotary shaker). The columns 
were washed three times with 1 column volume (CV) of resuspension buffer and eluted with seven 
fractions of 0.5 CV of resuspension buffer containing 5 mM desthiobiotin.  The first flow through 
fraction was loaded again onto a column containing 3 mL of pre‐equilibrated slurry of Strep-Tactin 
column material and the purification step was repeated. The elution fractions were analyzed on a 
12% polyacrylamide Tricine-SDS gel, followed by Coumassie staining. The fractions containing 
protein (typically elution 2-6 were pooled, concentrated and purified on a Hitrap Heparin HP 
column equilibrated with 50 mM NaH2PO4 pH 8.0, 2.5 mM DTT by a gradient of NaCl 
concentration from 0 to 1 M in 5 min with a flow of 1 mL/min. The elution fractions were analyzed 
on a 12% polyacrylamide Tricine-SDS gel, followed by Coumassie staining and the fractions 
containing protein were pooled and concentrated. The concentration of the proteins was measured 
with Nanodrop 2000 using the calculated extinction coefficient for monomer ε280= 25440 M‐1 cm‐
1. Typical expression yields were between 10-20 mg/L. UPLC-MS traces were recorded for each 
LmrR mutant. 
Table 4 Primers used for site-directed mutagenesis (fw: forward primer, rv: reverse primer). Single point mutations in 
bold. 
Primer Sequence (5’ → 3’) 
LmrR F93C_fw ATGCGACTTGCCTGCGAATCTTGGTCA 
LmrR F93C_rv TGACCAAGATTCGCAGGCAAGTCGCAT 
LmrR E104C_fw CGATAAAATTATTTGCAATTTAGAAGCAA 
LmrR E104C_rv TTGCTTCTAAATGCAAATAATTTTATCG 
LmrR H86C_fw CAGAGATTGGTTGCGAAAATATGCG 
LmrR H86C_rv CGCATATTTTCGCAACCAATCTCTG 
 




4.6.5 LmrR_bipyridine conjugates:  
Proteins were eluted from the cation exchange column, concentrated (1.5-2 mL, 250-300 µM) and 
dialyzed against 1 L of degassed 50 mM NaH2PO4 pH 7.8, 150 mM NaCl buffer overnight. A 10 
times molar excess of N-([2,2’-bipyridin]-5-yl methyl)-2-bromoacetamide dissolved in a small 
amount of DMSO (final concentration around 10%) was added to the protein solution under Ar 
and in the dark. The solution was mixed for 8 h at 4 °C after which the protein was dialyzed twice 
against 1 L of 20 mM MOPS pH 7.0, 500 mM NaCl. UPLC-MS of the resulting proteins were 
recorded for each conjugate. The concentration of the proteins was measured with a Nanodrop 
2000 using ε=40195 M-1cm-1. 
 
4.6.6 Size exclusion chromatography  
100 µL of the sample was injected onto a Superdex 75 10/300 GL column pre-equilibrated with 
20 mM MOPS pH 7.0 500 mM NaCl as buffer (flow 0.5 mL/min). Analytical size exclusion 
chromatograms were recorded of LmrR_bipyridine conjugates, after Strep-tag and Heparin 
purification, and of the conjugates after incubation with one equivalent of Fe2+ and Zn2+.  
 








































































Figure 12: Analytical size exclusion chromatography of LmrR cysteine mutants, LmrR_bipyridine conjugates 
and respective complexes with Fe2+ and Zn2+. 
Table 5 ESI (+) of wt-LmrR and LmrR cysteine mutants from UPLC-MS 
Protein 
 
MWobserved (Da) MWcalculated (Da) (-Met) 
wt-LmrR 14672 14669 
LmrR F93C 14625 14625 
LmrR E104C 14648 14643 
LmrR H86C 14636 14636 
 
Table 6 ESI (+) of LmrR_bipyridine conjugates from UPLC-MS 
Protein 
 
MWobserved (Da) MWcalculated (Da) (-Met) 
LmrR F93C 14850 14850 
LmrR E104C 14867 14868 




No significant deviations from the dimeric structure of LmrR were observed upon introduction of 
the bipyridine unit, as well as after Zn2+ coordination. Appearance of higher order conjugates was 
observed for LmrR E104C_bpy and LmrR H86C_bpy upon coordination of Fe2+. The nature of 
these conjugates is still be established. 
4.6.7 UV-visible titrations  
5 mM stock solutions of Zn(NO3)2·6H2O, FeSO4·7H2O were prepared by dissolving the salts in 
milliQ water containing 0.1% HCl. 1 mM working solution of metal salts were prepared by diluting 
the stock solutions in milliQ water. Protein solutions (22.5 µM, dimer, 200 µL) in 50 mM NaH2PO4 
pH 7.0, 500 mM NaCl were added to a 1.5 mL cuvette and titrated with 1 mM working solutions 
of metal salts (2.5 µL each addition, 0.27 eq.). UV-visible spectra were recorded at 25 °C from 
220 nm to 800 nm. No incubation time was necessary to obtain a stable signal. Apparent 
dissociation constants KD reported in Table 1 were obtained assuming a 1:1 binding stoichiometry 
using non-linear regression analysis (Origin) employing the following equation:   
















The reported apparent dissociation constants are the average of two independent experiments 
performed with two independent batches of LmrR_bipyridine conjugates and the error bars 
correspond to the standard deviation.  
4.6.8 Job’s plot 
A 100 µM stock solution of protein conjugates in 50 mM NaH2PO4 pH 7.0, 500 mM NaCl and a 
200 µM working solution of FeSO4·7H2O in milliQ water (prepared as described before) were 
mixed to obtain 6 solutions with different molar fractions of metal (0, 0.08, 0.17, 0.33, 0.50, 0.58) 
corresponding to metal:protein ratios of 0, 0.09, 0.20, 0.50, 1.00, 1.40. The solutions were mixed 
and incubated at room temperature for 30 min and then transferred to 1.5 mL cuvette. UV-visible 
spectra were recorded at 25 °C from 220 to 800 nm. 
4.6.9 Fluorescence titrations: binding of Hoechst 33342 
Titrations were performed with 0.2 µM solutions of protein dimer (2 mL) in 20 mM MOPS pH 
7.0, 500 mM NaCl titrated with a 8 µM solution of Hoechst 33342 in water (10 µL each addition, 
0.2 eq). 5 mM stock solution of Hoechst 33342 was prepared by dissolving the solid in milliQ 
water. The solution was immediately frozen after use and stored in the dark. By subsequent 
dilutions, a 8 µM solution of Hoechst 33342 in milliQ water was prepared. 20 µM protein 
conjugates solutions (dimer) in 20 mM MOPS pH 7.0, 500 mM NaCl were prepared and then 
diluted twice by a factor of 10. Fluorescence spectra were recorded with excitation and emission 
wavelengths of 355 and 457 nm, respectively. 
4.6.10 ICP-AES 
The metal content in each protein conjugate was determined by ICP-AES. LmrR_bipyridine 
conjugates in 20 mM MOPS pH 7.0, 500 mM NaCl were incubated with equimolar amount of 
metal salt in order to form the 1:1 complex LmrR dimer:M2+. Possible unbound metal was removed 
via dialysis in the same buffer. Samples were divided into three fractions. The first fraction was 
directly analyzed via ICP-AES to quantify the amount of metal bound to the protein in order to 
confirm the stoichiometry of the complexes formed (Table 7, entries 1 and 4). The second fraction 
and third fractions were incubated with an equimolar amount of [Cu(phen)(NO3)2] or Cu(NO3)2. 
Unbound metal was removed by dialysis prior to ICP analysis against 20 mM MOPS pH 7.0, 500 
mM NaCl (Table 7, entries 2-3 and 5-6). Samples for ICP-AES analysis were prepared by dilution 
of a solution of protein (around 1 mL) with 4 mL of 8 M urea in double distilled water and 1 mL 
to 10% v/v HNO3. Unfolding the protein was necessary to prevent protein precipitation in the 
acidic conditions necessary for the ICP analysis. The efficiency of dialysis for the removal of 
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unbound metal form the protein sample was tested using the non-metal binding wt-LmrR. 
Incubation with 2 ppm of Zn2+ prior to dialysis resulted complete recovery of Zn2+ (Table 7, entry 
7). After dialysis overnight against 1 L of 20 mM MOPS buffer pH 7.0, 500 mM NaCl the amount 
of Zn2+ detected via ICP was <0.1 ppm (Table 7, entry 8). Compared to the initial amount of Zn2+ 
added to the solution (2 mg/L), this result indicates that dialysis is a viable strategy to remove Zn2+ 




Catalytic reactions were performed in 150 µL total volume containing 22 µM [Cu(phen)(NO3)2] 
(2.2 mol%) and 30 µM LmrR_bpy conjugates (dimer, 1.3 equivalents), 1 mM of substrate 1 and 2 
in 20 mM MOPS pH 7.0, 500 mM NaCl. The reactions were incubated at 4 °C for 72 h after which 
50 µL of a 1 mM solution of 2-phenylquinoline were added. The reaction mixtures were extracted 
3 times with 500 µL diethylether and the organic layer was dried over Na2SO4 and evaporated in 
vacuo. The resulting products were redissolved in 150 µL heptane:isopropanol 9:1 and analyzed 
by chiral HPLC. Yields of all the catalytic reactions are based on peak areas at 275 nm using 2-




Table 7 Results of ICP-AES measurements on LmrR_E104C_bpy complexes with Fe2+ and Zn2+ 




expected 1 LmrR_E104C_bpy + Zn2+ 0.931 0.9 
2 LmrR_E104C_bpy+ Zn2+ + [Cu(phen)(NO3)2] 0.802 0.9 
3 LmrR_E104C_bpy+ Zn2+ + Cu(NO3)2 0.452 0.9 
4 LmrR_E104C_bpy+ Fe2+ 0.788 0.9 
5 LmrR_E104C_bpy+ Fe2+ + [Cu(phen)(NO3)2] 0.691 0.9 
6 LmrR_E104C_bpy+ Fe2+ + Cu(NO3)2 0.695 0.9 
Controls   
7 wt-LmrR + Zn2+ (no dialysis) 2.19 2.0 
8 wt-LmrR + Zn2+   <0.1 - 
 
Table 8 Results of vinylogous Friedel−Crafts alkylation reactions  
Entry Catalyst Yield 
(%)a 
TONb ee (%)c 
Further study: Excess of metal ions    
9 LmrR E104C_bpy+3eq Fe2+ 43±9 18±4 72±5 (-) 
10 LmrR E104C_bpy+6eq Fe2+ 38±3 16±1 71±4 (-) 
11 LmrR E104C_bpy+3eq Zn2+ 19±2 8±1 34±4 (-) 
12 LmrR E104C_bpy+6eq Zn2+ 24±4 10±2 24±6 (-) 
13 LmrR E104C_bpy+10eq Zn2+ 30±3 12±1 19±3 (-) 
Control reactions    
3 wt-LmrR+Fe2+ 71±5 29±2 91±0 (-) 
4 wt-LmrR+Zn2+ 67±2 28±1 90±0 (-) 
5 wt-LmrR+6eq Fe2+ 64±1 27±0 91±0 (-) 
6 wt-LmrR+6eq Zn2+ 55±19 23±8 87±0 (-) 
7 wt-LmrR+[Fe(bpy)3]
2+ 61±1 26±0 90±0 (-) 
8 wt-LmrR+[Zn(bpy)3]
2+ 68±1 28±0 91±0 (-) 
 
Same reaction conditions as in Table 2. aYields were determined by HPLC and using 2-phenylquinoline 
as internal standard. Errors listed are standard deviations. bTurnover numbers (TON) were determined by 
dividing the concentration of the product by the catalyst concentrations. cSign of rotation was assigned 




wt-LmrR was incubated with 1 eq of Fe2+ and Zn2+ (Table 8 entries 3-4) or 1 eq Fe2+ and Zn2+  in 
presence of 1 eq of bipyridine (Table 8 entries 7-8). The latter set of experiment will result in a 
solution containing wt-LmrR and a mixture of bipyridine_M2+ complexes, with [M(bpy)3]2+ being 
presumably the most abundant and free M2+ in solution. The metalloenzymes were then prepared 
in situ by self-assembly of [Cu(phen)(NO3)2] (22 μM) with a slight excess (1.3 equivalents) of 
LmrR_bipyridine_M2+ complex (30 μM) in 20 mM MOPS, pH 7.0, 500 mM NaCl. The mixtures 
were incubated at 4 °C for 30 minutes and the catalytic reactions initiated by addition of 1 mM of 
each substrate. Reactions were run at 4 °C for 72 h, after which the products were isolated and 
analyzed by chiral HPLC.   
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